Unknown

Dataset Information

0

A live vaccine rapidly protects against cholera in an infant rabbit model.


ABSTRACT: Outbreaks of cholera, a rapidly fatal diarrheal disease, often spread explosively. The efficacy of reactive vaccination campaigns-deploying Vibrio cholerae vaccines during epidemics-is partially limited by the time required for vaccine recipients to develop adaptive immunity. We created HaitiV, a live attenuated cholera vaccine candidate, by deleting diarrheagenic factors from a recent clinical isolate of V. cholerae and incorporating safeguards against vaccine reversion. We demonstrate that administration of HaitiV 24 hours before lethal challenge with wild-type V. cholerae reduced intestinal colonization by the wild-type strain, slowed disease progression, and reduced mortality in an infant rabbit model of cholera. HaitiV-mediated protection required viable vaccine, and rapid protection kinetics are not consistent with development of adaptive immunity. These features suggest that HaitiV mediates probiotic-like protection from cholera, a mechanism that is not known to be elicited by traditional vaccines. Mathematical modeling indicates that an intervention that works at the speed of HaitiV-mediated protection could improve the public health impact of reactive vaccination.

SUBMITTER: Hubbard TP 

PROVIDER: S-EPMC6500431 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

A live vaccine rapidly protects against cholera in an infant rabbit model.

Hubbard Troy P TP   Billings Gabriel G   Dörr Tobias T   Sit Brandon B   Warr Alyson R AR   Kuehl Carole J CJ   Kim Minsik M   Delgado Fernanda F   Mekalanos John J JJ   Lewnard Joseph A JA   Waldor Matthew K MK  

Science translational medicine 20180601 445


Outbreaks of cholera, a rapidly fatal diarrheal disease, often spread explosively. The efficacy of reactive vaccination campaigns-deploying <i>Vibrio cholerae</i> vaccines during epidemics-is partially limited by the time required for vaccine recipients to develop adaptive immunity. We created HaitiV, a live attenuated cholera vaccine candidate, by deleting diarrheagenic factors from a recent clinical isolate of <i>V. cholerae</i> and incorporating safeguards against vaccine reversion. We demons  ...[more]

Similar Datasets

| S-EPMC4045459 | biostudies-literature
| S-EPMC3201208 | biostudies-literature
| S-EPMC4401572 | biostudies-literature
| S-EPMC7896348 | biostudies-literature
| S-EPMC5587242 | biostudies-literature